Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: A pooled analysis

Tom J G Gevers, Frederik Nevens, Vicente Torres, Marie C Hogan, Joost P H Drenth

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background & Aims: Somatostatin analogues reduce liver volumes in polycystic liver disease. However, patients show considerable variability in treatment responses. Our aim was to identify specific patient, disease or treatment characteristics that predict response in polycystic liver disease during somatostatin analogue therapy. Methods: We pooled the individual patient data of four trials that evaluated long-acting somatostatin analogues (120 mg lanreotide or 40 mg octreotide) for 6-12 months in polycystic liver disease patients. We performed uni- and multivariate linear regression analysis with preselected patient, disease and drug variables to identify independent predictors of response, defined as per cent change in liver or kidney volume (in ADPKD subgroup). All analyses were adjusted for baseline liver volume and centre. Results: We included 153 polycystic liver disease patients (86% female, median liver volume 4974 ml) from three international centres, all treated with octreotide (n = 70) or lanreotide (n = 83). Mean reduction in liver volume was 4.4% (range -31.6 to +9.4%). Multivariate linear regression revealed that elevated baseline alkaline phosphatase was associated with increased liver volume reduction during therapy (-2.7%, 95% CI -5.1 to -0.2%, P = 0.04), independently of baseline liver volume. Somatostatin analogue type, underlying diagnosis and eGFR did not affect response. In our ADPKD subpopulation (n = 100), elevated alkaline phosphatase predicted liver volume reduction (-3.2%, P = 0.03) but did not predict kidney volume reduction (+0.1%, P = 0.97). Total gastro-intestinal symptom severity decreased with therapy in a subgroup analysis (n = 95; P <0.001). Conclusion: Alkaline phosphatase is a liver-specific, independent predictor of response in polycystic liver disease during somatostatin analogue therapy.

Original languageEnglish (US)
JournalLiver International
DOIs
StateAccepted/In press - 2015

Fingerprint

Somatostatin
Alkaline Phosphatase
Liver
Autosomal Dominant Polycystic Kidney
Octreotide
Therapeutics
Linear Models
Kidney
Polycystic liver disease
Regression Analysis
Pharmaceutical Preparations

Keywords

  • ADPKD
  • ADPLD
  • Alkaline phosphatase
  • Drug therapy
  • Hepatic cyst
  • Somatostatin

ASJC Scopus subject areas

  • Hepatology

Cite this

Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy : A pooled analysis. / Gevers, Tom J G; Nevens, Frederik; Torres, Vicente; Hogan, Marie C; Drenth, Joost P H.

In: Liver International, 2015.

Research output: Contribution to journalArticle

@article{9e7f5767216f404ab6fc5044821b97c0,
title = "Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: A pooled analysis",
abstract = "Background & Aims: Somatostatin analogues reduce liver volumes in polycystic liver disease. However, patients show considerable variability in treatment responses. Our aim was to identify specific patient, disease or treatment characteristics that predict response in polycystic liver disease during somatostatin analogue therapy. Methods: We pooled the individual patient data of four trials that evaluated long-acting somatostatin analogues (120 mg lanreotide or 40 mg octreotide) for 6-12 months in polycystic liver disease patients. We performed uni- and multivariate linear regression analysis with preselected patient, disease and drug variables to identify independent predictors of response, defined as per cent change in liver or kidney volume (in ADPKD subgroup). All analyses were adjusted for baseline liver volume and centre. Results: We included 153 polycystic liver disease patients (86{\%} female, median liver volume 4974 ml) from three international centres, all treated with octreotide (n = 70) or lanreotide (n = 83). Mean reduction in liver volume was 4.4{\%} (range -31.6 to +9.4{\%}). Multivariate linear regression revealed that elevated baseline alkaline phosphatase was associated with increased liver volume reduction during therapy (-2.7{\%}, 95{\%} CI -5.1 to -0.2{\%}, P = 0.04), independently of baseline liver volume. Somatostatin analogue type, underlying diagnosis and eGFR did not affect response. In our ADPKD subpopulation (n = 100), elevated alkaline phosphatase predicted liver volume reduction (-3.2{\%}, P = 0.03) but did not predict kidney volume reduction (+0.1{\%}, P = 0.97). Total gastro-intestinal symptom severity decreased with therapy in a subgroup analysis (n = 95; P <0.001). Conclusion: Alkaline phosphatase is a liver-specific, independent predictor of response in polycystic liver disease during somatostatin analogue therapy.",
keywords = "ADPKD, ADPLD, Alkaline phosphatase, Drug therapy, Hepatic cyst, Somatostatin",
author = "Gevers, {Tom J G} and Frederik Nevens and Vicente Torres and Hogan, {Marie C} and Drenth, {Joost P H}",
year = "2015",
doi = "10.1111/liv.12986",
language = "English (US)",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy

T2 - A pooled analysis

AU - Gevers, Tom J G

AU - Nevens, Frederik

AU - Torres, Vicente

AU - Hogan, Marie C

AU - Drenth, Joost P H

PY - 2015

Y1 - 2015

N2 - Background & Aims: Somatostatin analogues reduce liver volumes in polycystic liver disease. However, patients show considerable variability in treatment responses. Our aim was to identify specific patient, disease or treatment characteristics that predict response in polycystic liver disease during somatostatin analogue therapy. Methods: We pooled the individual patient data of four trials that evaluated long-acting somatostatin analogues (120 mg lanreotide or 40 mg octreotide) for 6-12 months in polycystic liver disease patients. We performed uni- and multivariate linear regression analysis with preselected patient, disease and drug variables to identify independent predictors of response, defined as per cent change in liver or kidney volume (in ADPKD subgroup). All analyses were adjusted for baseline liver volume and centre. Results: We included 153 polycystic liver disease patients (86% female, median liver volume 4974 ml) from three international centres, all treated with octreotide (n = 70) or lanreotide (n = 83). Mean reduction in liver volume was 4.4% (range -31.6 to +9.4%). Multivariate linear regression revealed that elevated baseline alkaline phosphatase was associated with increased liver volume reduction during therapy (-2.7%, 95% CI -5.1 to -0.2%, P = 0.04), independently of baseline liver volume. Somatostatin analogue type, underlying diagnosis and eGFR did not affect response. In our ADPKD subpopulation (n = 100), elevated alkaline phosphatase predicted liver volume reduction (-3.2%, P = 0.03) but did not predict kidney volume reduction (+0.1%, P = 0.97). Total gastro-intestinal symptom severity decreased with therapy in a subgroup analysis (n = 95; P <0.001). Conclusion: Alkaline phosphatase is a liver-specific, independent predictor of response in polycystic liver disease during somatostatin analogue therapy.

AB - Background & Aims: Somatostatin analogues reduce liver volumes in polycystic liver disease. However, patients show considerable variability in treatment responses. Our aim was to identify specific patient, disease or treatment characteristics that predict response in polycystic liver disease during somatostatin analogue therapy. Methods: We pooled the individual patient data of four trials that evaluated long-acting somatostatin analogues (120 mg lanreotide or 40 mg octreotide) for 6-12 months in polycystic liver disease patients. We performed uni- and multivariate linear regression analysis with preselected patient, disease and drug variables to identify independent predictors of response, defined as per cent change in liver or kidney volume (in ADPKD subgroup). All analyses were adjusted for baseline liver volume and centre. Results: We included 153 polycystic liver disease patients (86% female, median liver volume 4974 ml) from three international centres, all treated with octreotide (n = 70) or lanreotide (n = 83). Mean reduction in liver volume was 4.4% (range -31.6 to +9.4%). Multivariate linear regression revealed that elevated baseline alkaline phosphatase was associated with increased liver volume reduction during therapy (-2.7%, 95% CI -5.1 to -0.2%, P = 0.04), independently of baseline liver volume. Somatostatin analogue type, underlying diagnosis and eGFR did not affect response. In our ADPKD subpopulation (n = 100), elevated alkaline phosphatase predicted liver volume reduction (-3.2%, P = 0.03) but did not predict kidney volume reduction (+0.1%, P = 0.97). Total gastro-intestinal symptom severity decreased with therapy in a subgroup analysis (n = 95; P <0.001). Conclusion: Alkaline phosphatase is a liver-specific, independent predictor of response in polycystic liver disease during somatostatin analogue therapy.

KW - ADPKD

KW - ADPLD

KW - Alkaline phosphatase

KW - Drug therapy

KW - Hepatic cyst

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=84949035713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949035713&partnerID=8YFLogxK

U2 - 10.1111/liv.12986

DO - 10.1111/liv.12986

M3 - Article

C2 - 26481454

AN - SCOPUS:84949035713

JO - Liver International

JF - Liver International

SN - 1478-3223

ER -